Patrick JOHNSON is Executive Vice President, Corporate Research & Sciences at Dassault Systèmes. His mission is to define the scientific bases of the company’s solutions and invent disruptive technologies for the Industry Renaissance.
After joining in 1996, he held various positions in R&D, from Product Lifecycle Management foundations to product design for the CATIA flagship brand. In 2001, leading the Artificial Intelligence department, he contributed to important new practices now adopted in the industry for knowledge & know-how capture and automation.
Head of Research in 2004, he initiated many strategic technologies, resulting in key innovative products and patents and significantly grew the innovation ecosystem promoting multiple public/private partnerships with prestigious research institutes.
Finally, he launched a new diversification field for the company, with the BioIntelligence European research program, resulting in an innovative modeling, simulation and big data application suite for the life sciences sector, and the creation of the BIOVIA brand.
Mr. Johnson is based at 3DS world headquarters near Paris and is a member of the National Academy of Technology as well as of the scientific board of INRIA.
Dr. Hoganson is an Assistant in Cardiac Surgery, Department of Cardiac Surgery at Boston Children’s Hospital, and is an Instructor of Surgery at Harvard Medical School. His clinical focus is on neonates and children with congenital heart disease. Dr. Hoganson is active in the cardiac assist device and heart and lung transplant programs. He has co-lead development of patient-specific 3D modeling and computational flow modeling of complex cardiac disease for improved pre-operative planning and intraoperative guidance. The clinical modeling group has started a clinical consult service providing modeling services for the patient in the heart center. His lab also focuses on the development of medical devices to improve the safety and effectiveness of cardiac surgery. He is board-certified in Thoracic Surgery and Congenital Heart Surgery. Dr. Hoganson has a background in engineering and industry experience developing cardiovascular medical devices prior to medical school. He graduated from the Temple University School of Medicine in 2004 and completed his general surgery residency and CT fellowship at the Washington University in St. Louis, and completed a congenital cardiac surgery fellowship at the Boston Children’s Hospital in 2016.
Dr. Eytan Abraham heads Lonza Personalized Medicine, which focuses on developing and bringing to market solutions that enable research and development, scale-out, and commercialization of patient scale cell therapies, with an emphasis on decentralized and point of care manufacturing.
Prior to this Eytan led Lonza’s Cell and Viral Therapy R&D for five years, focusing on developing manufacturing solutions for the Cell and Gene therapy continuum.
Prior to Lonza, Dr. Abraham was head of therapeutic pipeline development at Pluristem Therapeutics, developing stem cell therapies for cardiovascular indications.
Dr. Abraham holds a Ph.D. in developmental and molecular biology from the University of Maryland Biotechnology Institute, and a post-doctorate in cell therapy and tissue engineering from the Harvard-MIT Biomedical Engineering Center and Harvard Medical School.
David Fajenbaum, MD, MBA, MSc, is an Assistant Professor of Medicine at the University of Pennsylvania, Associate Director of the Penn Orphan Disease Center, Founding Director of the Center for Cytokine Storm Treatment & Laboratory (CSTL), and Executive Director of the Castleman Disease Collaborative Network (CDCN). He is also the national bestselling author of 'Chasing My Cure: A Doctor's Race to Turn Hope Into Action' (http://www.ChasingMyCure.com) and a patient battling idiopathic multicentric Castleman disease (iMCD). One of the youngest individuals ever appointed to the faculty at Penn Medicine and one of the top 1 percent youngest grant awardees of a leading NIH grant, Dr. Fajenbaum leads multiple basic, translational, and clinical research studies at Penn and is in his longest remission ever thanks to a precision treatment that he identified, which had never been used before for iMCD. Dr. Fajgenbaum has been profiled in a cover story by The New York Times as well as by Good Morning America, CNN, and The Today Show.
Claire Biot is Vice President, Life Sciences Industry, Dassault Systèmes, where she is responsible for helping companies digitally transform their approach to scientific innovation by using the 3DEXPERIENCE platform to catalyze the next generation of therapeutics. Claire was also recently appointed to the Board of Directors at Mauna Kea.
Previously, she was the manager of industrial methods at the biopharmaceutical company LFB, then head of the division, health product pricing, and reimbursement at the French Ministry of Health. Most recently, she was managing director of Agence générale des équipements et produits de santé (AGEPS), France’s central agency for health products and technologies, and a subsidiary of Greater Paris University Hospitals (AP-HP).
In addition to engineering degrees from France’s Ecole Polytechnique and the Corps des mines program, Claire Biot earned a Master of Science degree in life sciences from the Watson School of Biological Sciences in New York, and a doctorate in immunology from the Institut Pasteur. She has also been an active member of several World Health Organization working groups.